Composition:
Adalimumab 40 mg/0.8 mL
Mabura 40 mg/0.8 mL Pen contains Adalimumab, a powerful monoclonal anti-tumor necrosis factor alpha (TNF-alpha) antibody used to manage a wide range of inflammatory diseases. It effectively treats conditions such as rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and psoriasis, providing relief from pain, swelling, and joint stiffness while improving physical function.
By targeting TNF-alpha, a key protein involved in inflammation, Mabura 40 mg/0.8 mL Pen helps reduce immune system overactivity, preventing further joint or tissue damage. This medication is administered via subcutaneous injection and should only be used under medical supervision. Before use, inform your doctor about any heart, kidney, or liver conditions, as well as any other medications you are taking.
*To be consumed as directed by physician.
Consuming alcohol with Mabura 40 mg/0.8 mL Pen does not cause any known harmful side effects.
PregnancyMabura 40 mg/0.8 mL Pen is generally considered safe during pregnancy. Animal studies indicate little to no adverse effects on the developing baby; however, human studies are limited. Always follow your doctor's advice.
BreastfeedingMabura 40 mg/0.8 mL Pen is likely safe during breastfeeding. Limited human data suggests it does not pose a significant risk to the baby. Consult your doctor before use.
DrivingMabura 40 mg/0.8 mL Pen may cause dizziness, vision disturbances, or a spinning sensation, which can impair your ability to drive. Avoid driving if you experience these side effects.
KidneyThere is limited data on the use of Mabura 40 mg/0.8 mL Pen in patients with kidney disease. Seek medical advice before use.
LiverThe effects of Mabura 40 mg/0.8 mL Pen on liver health are not well-documented. Consult your doctor for guidance.
